Composition and method for treatment of MRSA
AssigneeOndine International, Ltd.
InventorsCale Street, Nicolas Loebel, Lisa Pedigo
Life of this patent
Estimating the term…
Abstract
The present invention provides a photosensitizing composition for treatment of MRSA comprising a photosensitizer and chlorhexidine and a pharmaceutically acceptable carrier. The present invention also provides a method for reducing disease causing microbes comprising: applying the composition comprising a photosensitizer, chlorhexidine at a concentration of more than about 0.01% and less than about 2% v/v, and a pharmaceutically acceptable carrier to a treatment site; and applying light to the treatment site at a wavelength absorbed by the photosensitizer so as to reduce the microbes at the treatment site.
Claims20
A composition for treatment of Methicillin-resistant Staphylococcus aureus (“MRSA”) comprising:
- phenothiazine at a concentration from about 0.001% wt to about 1% wt;
- chlorhexidine;
- and
- a pharmaceutically acceptable carrier;
- wherein the composition is used for photodynamic disinfection of a treatment site containing MRSA wherein concentration of the chlorhexidine is between about 0.125% v/v to about 0.5% v/v.
A composition for photodynamic disinfection comprising:
- phenothiazine at a concentration from about 0.001% wt about 1% wt;
- chlorhexidine at a concentration between about 0.125% v/v and about 0.5% v/v;
- and
- a pharmaceutically acceptable carrier;
- wherein the composition is used for photodynamic disinfection of disease causing microbes.
A composition for photodynamic disinfection of microbes comprising:
- an effective amount of phenothiazine;
- an effective amount of chlorhexidine;
- and
- a pharmaceutically acceptable carrier;
- wherein the effective amount of phenothiazine and the effective amount of chlorhexidine produces a potentiation effect of antimicrobial efficacy during the photodynamic disinfection of microbes.
Dependencies are inferred from the claim text.